Key Takeaways
- • Cleveland Clinic and Khosla Ventures announced a strategic collaboration enabling the VC firm's portfolio companies to access Cleveland Clinic's clinical infrastructure for technology validation and testing across all development stages, from early concepts to commercial deployment.
- • Khosla Ventures portfolio companies gain direct access to Cleveland Clinic providers and clinicians, accelerating validation of innovations in artificial intelligence, digital health, and next-generation therapeutics within a real-world clinical environment.
- • Cleveland Clinic secures a structured pipeline to emerging healthcare technologies and gains leverage of Khosla Ventures' venture expertise and entrepreneurial network, combining the health system's research and clinical care capabilities with Silicon Valley-backed innovation.
- • Hal Paz, MD, operating partner at Khosla Ventures and former health system CEO, emphasized AI as "the most transformative technology of our lifetime" in healthcare, positioning the partnership to capitalize on this inflection point through clinical validation at a leading academic medical institution.
- • The collaboration addresses the critical bottleneck in healthcare innovation: bridging the gap between early-stage technology development and proven, scalable clinical adoption by providing startups direct demonstration opportunities with practicing clinicians.
Summary
Cleveland Clinic and Khosla Ventures formalized a strategic partnership designed to accelerate healthcare innovation by combining clinical infrastructure with venture-backed technology development. The collaboration, announced on October 14, 2025, creates a structured pathway for Khosla Ventures' portfolio companies to test, refine, and validate emerging technologies within Cleveland Clinic's clinical environment—one of the world's most respected health institutions.
Under the arrangement, portfolio companies within Khosla's healthcare investment portfolio gain direct access to Cleveland Clinic providers and clinical staff to showcase and test technologies at all stages of development, from clinical validation through commercial adoption. This access model removes a critical friction point in healthcare technology scaling: the ability to demonstrate value directly to practicing clinicians in operational settings. For startups, this arrangement accelerates the journey from concept to proven, scalable solutions. For Cleveland Clinic, the partnership provides a curated pipeline to emerging technologies in artificial intelligence, digital health, and next-generation therapeutics—areas where innovation velocity continues to accelerate.
Hal Paz, MD, operating partner at Khosla Ventures and former CEO of multiple large-scale health systems, framed AI as "the most transformative technology of our lifetime" and highlighted how the Cleveland Clinic relationship gives Khosla's companies a competitive advantage in validating and scaling AI-driven healthcare innovations. Geoff Vince, PhD, Chief of Cleveland Clinic Innovations, characterized the partnership as pairing the health system's established strengths in biomedical research, clinical care, and innovation infrastructure with Khosla Ventures' venture expertise and entrepreneur network.
The collaboration addresses a fundamental challenge in healthcare technology: the valley between early-stage innovation and clinical credibility. By providing portfolio companies direct engagement with a major academic medical center's clinicians and infrastructure, the partnership positions both organizations to move healthcare innovation more rapidly from proof-of-concept to real-world adoption, while giving Khosla Ventures companies demonstrable clinical validation—a critical asset for scaling healthcare technologies.
Under the arrangement, portfolio companies within Khosla's healthcare investment portfolio gain direct access to Cleveland Clinic providers and clinical staff to showcase and test technologies at all stages of development, from clinical validation through commercial adoption. This access model removes a critical friction point in healthcare technology scaling: the ability to demonstrate value directly to practicing clinicians in operational settings. For startups, this arrangement accelerates the journey from concept to proven, scalable solutions. For Cleveland Clinic, the partnership provides a curated pipeline to emerging technologies in artificial intelligence, digital health, and next-generation therapeutics—areas where innovation velocity continues to accelerate.
Hal Paz, MD, operating partner at Khosla Ventures and former CEO of multiple large-scale health systems, framed AI as "the most transformative technology of our lifetime" and highlighted how the Cleveland Clinic relationship gives Khosla's companies a competitive advantage in validating and scaling AI-driven healthcare innovations. Geoff Vince, PhD, Chief of Cleveland Clinic Innovations, characterized the partnership as pairing the health system's established strengths in biomedical research, clinical care, and innovation infrastructure with Khosla Ventures' venture expertise and entrepreneur network.
The collaboration addresses a fundamental challenge in healthcare technology: the valley between early-stage innovation and clinical credibility. By providing portfolio companies direct engagement with a major academic medical center's clinicians and infrastructure, the partnership positions both organizations to move healthcare innovation more rapidly from proof-of-concept to real-world adoption, while giving Khosla Ventures companies demonstrable clinical validation—a critical asset for scaling healthcare technologies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.